Trial Profile

An Open-label Multicenter Phase 2 Dose-evaluation Study of Altropane (123I) Injection for Striatal Dopamine Transporter Visualization Using SPECT Brain Imaging

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NAV 5001 (Primary)
Indications Parkinson's disease
Focus Diagnostic use
Sponsors GE Healthcare

Most Recent Events

06 Nov 2024 Status changed from recruiting to discontinued. ( Business Decision )
02 Feb 2024 Planned End Date changed from 22 Dec 2023 to 29 Mar 2024.
02 Feb 2024 Planned primary completion date changed from 22 Dec 2023 to 29 Mar 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com